- Report
- November 2025
- 150 Pages
Global
From €4337EUR$4,850USD£3,708GBP
- Report
- November 2025
- 150 Pages
Global
From €4337EUR$4,850USD£3,708GBP
- Report
- September 2025
- 150 Pages
Global
From €4337EUR$4,850USD£3,708GBP
- Report
- June 2026
- 200 Pages
North America
From €2674EUR$2,990USD£2,286GBP
- Report
- April 2026
- 75 Pages
United States
From €4248EUR$4,750USD£3,632GBP
- Report
- June 2024
- 252 Pages
Global
From €2191EUR$2,450USD£1,873GBP
- Report
- July 2024
- 133 Pages
Global
From €2674EUR$2,990USD£2,286GBP
- Report
- November 2020
- 263 Pages
Global
From €3130EUR$3,500USD£2,676GBP
- Report
- May 2021
- 219 Pages
Global
From €2459EUR$2,750USD£2,103GBP
- Report
- December 2024
- 100 Pages
Global
From €5321EUR$5,950USD£4,549GBP
- Report
- June 2024
- 70 Pages
United States
From €3533EUR$3,950USD£3,020GBP
- Report
- June 2026
- 116 Pages
Mexico
From €2682EUR$2,999USD£2,293GBP
From €4427EUR$4,950USD£3,785GBP
- Report
- August 2025
- 189 Pages
Global
From €3170EUR$3,545USD£2,711GBP
€3523EUR$3,939USD£3,012GBP
- Report
- August 2025
- 194 Pages
Global
From €3170EUR$3,545USD£2,711GBP
€3523EUR$3,939USD£3,012GBP
- Report
- August 2025
- 192 Pages
Global
From €3170EUR$3,545USD£2,711GBP
€3523EUR$3,939USD£3,012GBP
- Report
- August 2025
- 182 Pages
Global
From €3170EUR$3,545USD£2,711GBP
€3523EUR$3,939USD£3,012GBP
- Report
- August 2025
- 187 Pages
Global
From €3170EUR$3,545USD£2,711GBP
€3523EUR$3,939USD£3,012GBP
- Report
- August 2025
- 199 Pages
Global
From €3170EUR$3,545USD£2,711GBP
€3523EUR$3,939USD£3,012GBP
- Report
- August 2025
- 191 Pages
Global
From €3170EUR$3,545USD£2,711GBP
€3523EUR$3,939USD£3,012GBP

The Drug Eluting Balloon (DEB) market is a subset of the medical device industry. DEBs are used to treat peripheral artery disease (PAD) and coronary artery disease (CAD). They are designed to deliver a drug directly to the site of the blockage, allowing for improved efficacy and reduced side effects. DEBs are typically composed of a balloon catheter with a drug-eluting coating. The drug is released when the balloon is inflated, allowing for targeted delivery of the drug to the affected area.
DEBs have been shown to be effective in treating PAD and CAD, and are increasingly being used in clinical practice. They offer a minimally invasive alternative to traditional treatments such as stenting and bypass surgery.
Some companies in the DEB market include Medtronic, Boston Scientific, Abbott, and B. Braun. Show Less Read more